

March 23, 2026
Mochida Pharmaceutical Co., Ltd.
AYUMI Pharmaceutical Corporation

**Announcement of Manufacturing and Marketing Approval
for Tocilizumab BS MA in Japan**

Mochida Pharmaceutical Co., Ltd. (Head office: Shinjuku-ku, Tokyo, President: Naoyuki Mochida, hereinafter “Mochida”) and AYUMI Pharmaceutical Corporation (Head office: Chuo-ku, Tokyo, President: Jugo Tsumura, hereinafter “AYUMI”) announce that today Mochida obtained manufacturing and marketing approval for Tocilizumab BS MA (development code: RGB-19; hereinafter “the Product”) in Japan.

The Product is a Tocilizumab biosimilar jointly developed by Mochida and Gedeon Richter Plc. Under the collaboration agreement between Mochida and AYUMI concerning domestic commercialization of the Product, Mochida will supply the Product to AYUMI, and AYUMI will be responsible for sales.

Mochida and AYUMI have also collaborated on the commercialization of Etanercept BS MA, launched in 2018, and Adalimumab BS MA, launched in 2021. Through the launch of the Product, Mochida and AYUMI aim to further enhance treatment options for conditions such as rheumatoid arthritis and to meet the needs of patients and healthcare professionals.

Contact:

Mochida Pharmaceutical Co., Ltd.
Public Relations, Corporate Planning Department
E-mail: webmaster@mochida.co.jp
AYUMI Pharmaceutical Corporation
Business Planning Department
E-mail: dep_0101000@ayumi-pharma.com

[References]

Summary of Tocilizumab BS MA

- Brand Name : Tocilizumab BS Intravenous Infusion 80mg MA
Tocilizumab BS Intravenous Infusion 200mg MA
Tocilizumab BS Intravenous Infusion 400mg MA
Tocilizumab BS Subcutaneous Injection 162mg Syringe MA
Tocilizumab BS Subcutaneous Injection 162mg Auto-Injector MA
- Generic Name : Tocilizumab (genetical recombination) [Tocilizumab Biosimilar 2]
- Indications : Tocilizumab BS Intravenous Infusion 80mg MA
Tocilizumab BS Intravenous Infusion 200mg MA
Tocilizumab BS Intravenous Infusion 400mg MA
- The following diseases in patients who have had an inadequate response to existing treatments:
Rheumatoid arthritis (including the inhibition of progression of structural joint damage), Polyarticular-course juvenile idiopathic arthritis, Systemic juvenile idiopathic arthritis
 - Improvement of various symptoms and laboratory findings limited to patients for whom lymph node resection is not indicated (increased C-reactive protein, increased fibrinogen, increased erythrocyte sedimentation rate, decreased hemoglobin, decreased albumin, generalized fatigue) associated with Castleman's disease
 - Cytokine release syndrome induced by cancer therapy
 - SARS-CoV-2 pneumonia (limited to patients requiring oxygen intervention)
- Tocilizumab BS Subcutaneous Injection 162mg Syringe MA
Tocilizumab BS Subcutaneous Injection 162mg Auto-Injector MA
- The following disease in patients who have had an inadequate response to the existing treatments:
- Rheumatoid arthritis (including the inhibition of progression of structural joint damage)
- Approved Date : March 23, 2026
- Manufacturer : Mochida Pharmaceutical Co., Ltd.
- Distributor : AYUMI Pharmaceutical Corporation

###

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.